Latest Intelligence on Therapy Area in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Speedel/Novartis: Rasilez and the renin revolution

Novartis stands on the brink of launching the first innovative treatment for hypertension in over a decade, in the form of Rasilez (aliskiren), thanks to the efforts of the drug's development partner, Speedel. This vindicates the risk Speedel took back in 1998 when it set out to build a business based on big pharma cast-offs, something many believed was doomed to fail.

Published By Datamonitor
10 Mar 2006
CommentWire
CommentWire

Speedel/Novartis: hypertension hype or hope?

Speedel and Novartis' Rasilez, the first, orally available direct renin inhibitor, has demonstrated in a phase III trial that it is a safe addition to the current antihypertensive armamentarium. The results clearly show that the novel agent is a viable treatment option, but whether this clinical success can translate into commercial potential remains to be seen, as further hurdles await.

Published By Datamonitor
18 May 2006
CommentWire
CommentWire

Serono: the future is bright with Rebif

The regulator's decision to break the orphan drug status of Biogen's Avonex and allow Rebif's US sale is a massive boost to Serono's growth prospects. The resulting extra revenues should allow Serono to increase its comparatively weak pipeline through in-licensing deals - and also by going on the acquisition trail.

Published By Datamonitor
13 Mar 2002
CommentWire
CommentWire

Serono: Parkinson's drug deal will fit with Merck merger

The addition of safinamide to Serono's late stage R&D pipeline will fill the gap left by Merck KGaA's halted Parkinson's disease (PD) product, sarizotan, when the two companies merge to form Merck-Serono Biopharmaceuticals. However, the drug is not expected to have a large impact on the PD market and thus will not be a key growth driver for the company.

Published By Datamonitor
18 Oct 2006
CommentWire
CommentWire

Roche: Xelox to challenge FOLFOX in colorectal cancer

A phase III trial of Roche's Xelox regimen in colorectal cancer has proven successful, with the study finding Xelox to be as effective as FOLFOX, the current standard first-line treatment for metastatic colorectal tumors. However, numerous challenges still face Roche if the regimen is to make a significant impact upon the colorectal tumor market.

Published By Datamonitor
02 Aug 2006
CommentWire
CommentWire

Roche: XELOX regimen may offer advantages over FOLFOX-4

Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective.

Published By Datamonitor
23 Jan 2007
CommentWire
CommentWire

Roche: Xeloda gets warning on warfarin interaction

Like many drugs, and some foods, Xeloda interacts negatively with popular anticoagulant warfarin. This may reduce the use of Xeloda in cancer patients requiring anticoagulation. It also highlights the potential of AstraZeneca's new oral anticoagulant, ximelagatran, which is currently undergoing phase III trials and is not associated with the interactions that plague warfarin.

Published By Datamonitor
07 Nov 2001
CommentWire
CommentWire

Roche: T-20 demand will outstrip supply

Roche's new HIV drug, T-20, should launch next year. However, it already seems that producing sufficient quantities of T-20 will be a challenge - particularly before the full-scale production facility for the drug comes online. Roche will need to manage customer expectations carefully in the early stages of T-20's launch, or risk losing confidence.

Published By Datamonitor
06 Aug 2002
CommentWire
CommentWire

Roche: strengthening its HCV pipeline

In a new collaboration that could see InterMune earn up to $530 million, Roche has agreed to develop and commercialise HCV protease inhibitors held by the Californian biotech firm. The value of the deal reflects the commercial appeal of the HCV market and the importance of developing the right product in the face of strong competition from rival pharmaceutical companies.

Published By Datamonitor
18 Oct 2006
CommentWire
CommentWire

Roche: stopping Xenical from slimming down

Published By Datamonitor
10 Oct 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.